Market›Health Care›Biotechnology›Biotechnology
EXOZYMES INC

EXOZ

$10.31Nov 13, 2024 – Apr 24, 2026
Health CareBiotechnology$93M
MVM
-$2.4M
TD Variance
-2.143

Every news event mapped to its market reaction — 30 events, 18 months of data. No predictions, just what happened.

PositiveNegativeNo data· Dot size = magnitude · Scroll to zoom · Drag to pan
Hover to inspect

Want the full written briefing?

The chart shows what moved — the briefing shows why. Sourced, dated, no hot takes.

Subscribe on Substack →

News Events

DateReturnCategorySourceHeadline
2025-02-12+16.1%newsTradingViewEXOZ Stock Price and Chart — NASDAQ:EXOZ - TradingView
2026-04-01+15.5%earningsGuruFocus.comEXoZymes Inc (EXOZ) Q4 2025 Earnings Call Highlights: Strategic Advances Amid Financial Challenges
2024-11-19+15.1%newsSeeking AlphaInvizyne Technologies selected for $2M project to advance sustainable aviation fuel capabilities
2026-03-31+11.9%earningsMarketBeateXoZymes Q4 Earnings Call Highlights
2026-03-31+11.9%newsACCESS NewswireeXoZymes Provides Fourth Quarter and Full Year 2025 Update
2026-03-31+11.9%newsGlobeNewswireMDB Capital Holdings Provides 2025 Full Year Update and Shareholder Letter
2026-03-31+11.9%newsSeeking AlphaeXoZymes reports FY results
2026-03-31+11.9%newsStock TitaneXoZymes ends 2025 with $3.04M cash as financing round nears - Stock Titan
2026-03-31+11.9%newsStock TitaneXoZymes (NASDAQ: EXOZ) files updated NCTx investor presentation - Stock Titan
2026-04-08+10.7%newsStock Titan[Form 4] EXOZYMES INC. Insider Trading Activity - Stock Titan
2026-04-08+10.7%newsStock TitanEXOZYMES (NASDAQ: EXOZ) CCO receives 8,887-share stock grant - Stock Titan
2026-04-08+10.7%newsStock TitanEXOZYMES (EXOZ) VP awarded 3,999 common shares as stock grant - Stock Titan
2026-04-08+10.7%newsStock TitanEXOZYMES (EXOZ) CCO awarded 146,437 options and 62,759 restricted shares - Stock Titan
2026-04-08+10.7%newsStock TitanExozymes (EXOZ) CSO receives 5,332-share stock award - Stock Titan
2026-04-08+10.7%executiveStock TitanEXOZYMES (NASDAQ: EXOZ) Chief Commercial Officer files initial Form 3 - Stock Titan
2025-05-12+7.9%earningsSeeking AlphaeXoZymes reports Q1 results
2025-11-13-5.8%newssimplywall.stWe Think eXoZymes (NASDAQ:EXOZ) Needs To Drive Business Growth Carefully - simplywall.st
2026-02-10-3.8%newsACCESS NewswireWith Refreshed Brand eXoZymes Sharpens Pharmaceutical Focus to Drive Platform Leverage and Long-Term Value Creation
2025-02-20-2.7%earningsMarketBeateXoZymes (EXOZ) Stock Price, News & Analysis - MarketBeat
2026-03-18+2.6%newsACCESS NewswireSuccessful Pilot Scale Run with Cayman Chemical Validates eXoZymes' Technology and Scalability
2025-04-02+2.4%earningsSeeking AlphaeXoZymes GAAP EPS of -$0.89
2025-02-15-2.4%newsCNNsymbol__ Stock Quote Price and Forecast - CNN
2026-03-12+2.1%newsACCESS NewswireeXoZymes' CCO Damien Perriman to Present a NCT Solution at Next Week's MISTA Symposium
2026-04-07+1.4%earningsGuruFocus.comMDB Capital Holdings LLC (MDBH) Q4 2025 Earnings Call Highlights: Strategic Innovations and ...
2026-03-25+1.0%newsACCESS NewswireeXoZymes to Host Fourth Quarter and Full Year 2025 Results Conference Call on Tuesday March 31, 2026
2026-04-10-0.0%newsACCESS NewswireeXoZymes CCO, Damien Perriman, Outlines NCTx Strategy and the Commercial Path for Cell-Free Biomanufacturing on Grow Everything Podcast
2026-04-10-0.0%newsStock TitanExozymes (EXOZ) CSO logs small April open-market stock sales - Stock Titan
2026-04-10-0.0%legalStock TitaneXoZymes (EXOZ) files investor presentation tied to proposed securities offering - Stock Titan
2026-04-10-0.0%newsStock TitanWhy eXoZymes spun out NCTx to take NCT down the supplement path - Stock Titan
2024-11-13—newsSeeking AlphaInvizyne Technologies stock climbs 13% following $15M IPO
tickerdossier.comtickerdossier.substack.com